Home › Lupus › South Carolina › Charleston
Lupus clinical trials in Charleston, SC
4 studies for Lupus are looking for participants at sites in and around Charleston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- Medical University of South Carolina, Charleston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
- Medical University of South Carolina, Charleston
Systemic Lupus Erythematosus in Gullah Health
RecruitingObservational studyHealthy volunteers welcome
- Medical University of South Carolina, Charleston
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RecruitingPhase 1
- Medical University of South Carolina, Charleston
About Lupus
Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.
More about Lupus on MedlinePlus
Lupus trials in other cities
- New York City, NY18 studies
- Houston, TX13 studies
- Durham, NC12 studies
- Washington, DC10 studies
- Miami, FL10 studies
- Tampa, FL9 studies
- Philadelphia, PA9 studies
- Clearwater, FL8 studies
- Santa Monica, CA8 studies
- Oklahoma City, OK8 studies
- Boston, MA8 studies
- Los Angeles, CA8 studies
Other studies in Charleston
- Depression19 studies
- Stroke18 studies
- Heart Failure18 studies
- Post-Traumatic Stress Disorder16 studies
- Non-Small Cell Lung Cancer16 studies
- Prostate Cancer15 studies
- Cardiovascular Disease15 studies
- Head and Neck Squamous Cell Carcinoma14 studies
- Cancer (all types)14 studies
- Parkinson's Disease13 studies
- Interstitial Lung Diseases13 studies
- Breast Cancer12 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.